HOME >> MEDICINE >> NEWS
The Lancet Oncology and The Lancet Infectious Diseases

THE LANCET ONCOLOGY

THE TRUE COST OF A NUCLEAR DETERRENT

This months editorial covers the recent leaked report from the US Department of Health and Disease Control, showing the patterns of nuclear fallout across the US resulting from Cold War testing. The editorial discusses the impact of these data on cancer incidence and the worldwide effects of nuclear testing on the general population and military personnel. It concludes: 'It is easy to say that lessons should be learnt from the history of the nuclear deterrent, but unfortunately, with the escalation of the nuclear race in India and Pakistan, and the possibility of terrorist groups such as al-Qaeda acquiring materials to create crude nuclear devices, it is likely that the same mistakes will be repeated. We may never fully realise the true human cost of military advancement.'

REVIEWS

  • The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators
  • Use of minimally invasive oesophagectomy for cancer of the oesophagus
  • Clinical management of dyspnoea
  • Mediastinal (thymic) large B-cell lymphoma: where do we stand?
  • Culprit and victim - DNA topoisomerase II
  • Cancer causation: the Darwinian downside of past success?

THE LANCET INFECTIOUS DISEASES

ENOUGH TIME WASTED IN SOUTH AFRICA

This months Leading Edge editorial discusses the South African Governments reluctance to provide the antiretroviral drug nevirapine to pregnant women with HIV. The drug has been shown to be effective in preventing mother-to-child HIV-1 transmission; however the South African Government have recently launched an appeal to a March 11 court hearing which instructed them to make the drug available in state facilities offering HIV-1 counselling and testing.

REVIEWS

  • Epidemiology of drug-resistant malaria
  • p values for pathogens: statistica
    '"/>


Contact: Richard Lane
richard.lane@lancet.com
44-20-7424-4949
Lancet
1-Apr-2002


Page: 1 2

Related medicine news :

1. The Lancet calls for the creation of a world institute for risk evaluation
2. The Lancet calls for creation of Intl Commission on Global Responses to Complex Emergencies
3. Majority of authors retract 1998 Lancet paper-Lancet editor points to implications
4. The Lancet Oncology (TLO)
5. The Lancet Infectious Diseases (TLID)
6. The Lancet Neurology November press release
7. Lancet readers to join WHO election debate
8. The Lancet Oncology press release
9. The Lancet Neurology October press release
10. The Lancet neurology press release
11. The Lancet Neurology press release

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... Fort Myers, FL (PRWEB) , ... December 08, 2016 , ... ... that serves business owners and families in and around the Cape Coral area, is ... the Harry Chapin Food Bank of Southwest Florida. , The Harry Chapin Food Bank ...
(Date:12/8/2016)... KS (PRWEB) , ... December 08, 2016 , ... ... financial consultation services to families and business owners in and around central Kansas, ... provide assistance to at-risk youth in the region. , Headquartered in Wichita, Youth ...
(Date:12/7/2016)... Alexandria, VA (PRWEB) , ... December 07, 2016 ... ... nation are celebrating the passage of the most comprehensive mental health systems reform ... Congress, the support of the President, and the commitment of our elected officials ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... and deep lines by smoothing and tightening the skin of the face to ... to address facial aging with very little downtime, Silhouette Instalift is a novel, ...
(Date:12/7/2016)... (PRWEB) , ... December 07, ... ... it has acquired Presence Technology, S.L. (“Presence”) for a purchase price of ... adjustments and other considerations. Presence’s annual revenue is approximately $13.2 million. Headquartered ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... FALLS, N.J., Dec. 8, 2016 CANTEL MEDICAL CORP. ... income of $18,800,000, or $0.45 per diluted share, on a ... first quarter ended October 31, 2016. This compares with net ... of $153,779,000 for the first quarter ended October 31, 2015. ... first quarter ended October 31, 2016 to $21,323,000, or $0.51 ...
(Date:12/8/2016)... , Dec. 8, 2016   Mederi Therapeutics Inc . has announced regulatory ... Therapy, a non-surgical treatment for chronic gastroesophageal reflux disease (GERD). ... ... and broadcast during the Chinese Congress of Digestive Endoscopy, by Professor Jun Liu, Director ... , , "We are very ...
(Date:12/8/2016)... BEIJING , and SAN DIEGO , ... genomic services and solutions with cutting edge next-generation sequencing and ... biotechnology company; and the Genome Institute of ... (NovogeneAIT) – a new joint venture between Novogene and AITbiotech ... at Biopolis, Singapore .   ...
Breaking Medicine Technology:
Cached News: